Skip to content

Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney

Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney (Renal Pelvis)

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00959153
Enrollment
20
Registered
2009-08-14
Start date
2010-06-30
Completion date
2011-08-31
Last updated
2011-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Stones

Keywords

Fragmenting of kidney stones, extracorporeal shockwave lithotripsy

Brief summary

A total of 20 subjects presenting with urinary stone(s) in the kidney or ureter will be treated with an extracorporeal shockwave lithotripsy device to fragment the stones. Subjects will be followed for 14 days. If at the 14 day follow-up visit the subject continues to present with a stone size 4 mm or greater will have an option of retreatment or other intervention. If the subject consents to be retreated at this time, this subject will be followed up for another 14 days.

Interventions

DEVICELithoSpace Extracorporeal Shockwave Lithotripter

Shockwave therapy to break up kidney stones

Sponsors

Advance Shockwave Technology GmbH
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of a solitary Urinary stones in the renal pelvis or renal calyces or ureter * Presence of one stone greater than 4 mm and less than 12 mm

Exclusion criteria

* Urinary tract obstruction, acute or unresolved cholecystitis, cholangitis, pancreatitis or obstruction of the biliary duct system * Impaction of stone to be treated * Staghorn stones * Failed or inadequate lithotripsy procedure within 3 months prior to study * Coagulation abnormalities or anticoagulation therapy * Pregnant or females of child-bearing potential General, spinal or epidural anesthesia is contraindicated * Can not be positioned correctly for fluoroscopic imaging

Design outcomes

Primary

MeasureTime frame
stone fragmentation14 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026